Here are Friday's biggest analyst calls: Nvidia, SpaceX, Tesla, Palantir, Shopify, Oracle, Dell, Rocket Lab & more
Analysts initiated or updated coverage on several companies. Piper Sandler initiated Q2 Holdings as overweight, citing its growth potential. Bernstein initiated Shopify as outperform, highlighting its AI positioning. RBC initiated Dell as outperform with a $640 price target, citing AI infrastructure demand. UBS initiated Korsana Biosciences as buy with a $55 price target. Other notable mentions include Nvidia, SpaceX, Tesla, Palantir, and Oracle.
How this was made
The 30-second read
Why it matters
Collective upgrades may create short‑term buying pressure, but individual impact varies by company fundamentals.
Market read
The roundup provides fresh analyst sentiment that could influence intraday trading across multiple sectors.
What to watch
Potential valuation concerns and execution risks are not addressed in the brief coverage.
Background
The article aggregates new analyst coverage and rating changes for a range of U.S. stocks.
Ticker impact
Bernstein initiates Shopify as outperform, highlighting AI positioning.
Likely modest rally on the news.
AI focus aligns with market enthusiasm.
RBC initiates Dell as outperform, citing AI infrastructure demand.
Short-term upside expected.
AI demand is a strong catalyst for hardware makers.
Rothschild & Co reiterates Nvidia as buy, noting Hugging Face acquisition.
Likely maintains current uptrend.
Acquisition aligns with AI strategy.
JPMorgan initiates Old National Bancorp as overweight with a $32 target.
Modest upside expected.
Strong return metrics cited by analyst.
KeyBanc initiates Linde as overweight, calling it high‑quality.
Potential incremental gain.
Quality narrative may appeal to defensive investors.
Raymond James initiates Rocket Lab as outperform with an $80 target.
Short‑term upside likely.
Growth prospects in small‑sat market.
DA Davidson reiterates Palantir as buy, raising price target to $250.
Potential price lift.
AI sovereignty narrative resonates.
JPMorgan initiates Dianthus Therapeutics as buy with a $135 target.
Likely modest rally.
Early‑stage biotech volatility.
Market effects
Analyst initiations signal broader confidence in AI, cloud, and industrial sectors.
U.S. equities may see modest uplift across tech and industrial names.
Limited to U.S. listed firms; no direct global macro effect.
Counterpoint
Some investors may view the flurry of initiations as over‑optimistic, preferring wait‑and‑see.
Key entities
- analyst_firmPiper Sandler
Initiated Q2 Holdings as overweight.
- analyst_firmBernstein
Initiated Shopify as outperform.
